Early Effects of Metabolic Syndrome on ATP-Sensitive Potassium Channels from Rat Pancreatic Beta Cells

Metabolic syndrome (MS) is a cluster of metabolic signs that increases the risk of developing type 2 two diabetes mellitus and cardiovascular diseases. MS leads to pancreatic beta cell exhaustion and decreased insulin secretion through unknown mechanisms in a time-dependent manner. ATP-sensitive pot...

Full description

Saved in:
Bibliographic Details
Published inMetabolites Vol. 12; no. 4; p. 365
Main Authors Cruz-Cruz, Iskra, Bernate-Obando, Germán, Larqué, Carlos, Escalona, Rene, Pinto-Almazán, Rodolfo, Velasco, Myrian
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 18.04.2022
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Metabolic syndrome (MS) is a cluster of metabolic signs that increases the risk of developing type 2 two diabetes mellitus and cardiovascular diseases. MS leads to pancreatic beta cell exhaustion and decreased insulin secretion through unknown mechanisms in a time-dependent manner. ATP-sensitive potassium channels (K channels), common targets of anti-diabetic drugs, participate in the glucose-stimulated insulin secretion, coupling the metabolic status and electrical activity of pancreatic beta cells. We investigated the early effects of MS on the conductance, ATP and glybenclamide sensitivity of the K channels. We used rats fed with a high-sucrose diet (HSD) for 8 weeks as a MS model. In excised membrane patches, control and HSD channels showed similar unitary conductance and ATP sensitivity pancreatic beta cells in their K channels In contrast, MS produced variability in the sensitivity to glybenclamide of K channels. We observed two subpopulations of pancreatic beta cells, one with similar (Gly1) and one with increased (Gly2) glybenclamide sensitivity compared to the control group. This study shows that the early effects of MS produced by consuming high-sugar beverages can affect the pharmacological properties of K channels to one of the drugs used for diabetes treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2218-1989
2218-1989
DOI:10.3390/metabo12040365